Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
11 December, 2018 18:33 IST
Lupin receives tentative USFDA nod for generic Locoid lotion
Source: IRIS | 12 Feb, 2018, 04.20PM
Comments  |  Post Comment

Pharma major Lupin announced that it has received tentative approval for its Hydrocortisone Butyrate Lotion, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of Precision Dermatology, Inc.'s Locoid Lotion, 0.1%.

Lupin's Hydrocortisone Butyrate Lotion, 0.1% is the generic equivalent of Precision Dermatology, Inc.'s Locoid Lotion, 0.1%. It is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.

Hydrocortisone Butyrate Lotion, 0.1% had annual sales of approximate USD 16.1 million in the US (IQVIA MAT October 2017).

Shares of the company gained Rs 18.4, or 2.24%, to settle at Rs 839.30. The total volume of shares traded was 124,365 at the BSE (Monday).



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Wipro Digital to expand Asia Pacific design capabilities in Australia - 11-Dec-2018 09:26
Wipro Digital to expand Asia Pacific design capabilities in Australia - 11-Dec-2018 09:24
Lupin receives tentative USFDA approval for Apixaban tablets - 11-Dec-2018 09:20
Lupin receives EIR from USFDA for Indore facility - 10-Dec-2018 16:10
HCL Tech to acquire select IBM Software products for USD 1.8 bn - 07-Dec-2018 10:08
Wipro, Alfresco expand pact to offer digital transformation capabilities - 07-Dec-2018 09:59
Indian Hume Pipe Co receives contract worth Rs 2.04 bn - 06-Dec-2018 09:50
Infosys inaugurates technology and innovation hub in Hartford - 06-Dec-2018 09:46
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer